Elanco Completes Bayer Animal Health Acquisition
Ticker: ELAN · Form: 8-K · Filed: Jul 9, 2024 · CIK: 1739104
| Field | Detail |
|---|---|
| Company | Elanco Animal Health Inc (ELAN) |
| Form Type | 8-K |
| Filed Date | Jul 9, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1.3 billion, $1.3 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, completion, animal-health
TL;DR
Elanco just bought Bayer's animal health business, big move for the sector.
AI Summary
Elanco Animal Health Incorporated announced the completion of its acquisition of Bayer Animal Health on July 9, 2024. This strategic move is expected to significantly enhance Elanco's portfolio and market position in the animal health industry.
Why It Matters
This acquisition is a major step for Elanco, potentially reshaping the competitive landscape of the animal health market and impacting product availability and innovation.
Risk Assessment
Risk Level: medium — The integration of a large acquisition carries inherent risks related to operational synergy, market reception, and potential regulatory hurdles.
Key Players & Entities
- Elanco Animal Health Incorporated (company) — Registrant
- Bayer Animal Health (company) — Acquired Business
- July 9, 2024 (date) — Completion Date
FAQ
What was the exact date of the completion of the acquisition?
The acquisition was completed on July 9, 2024.
What is the name of the company filing this report?
The company filing this report is Elanco Animal Health Incorporated.
In which state is Elanco Animal Health Incorporated incorporated?
Elanco Animal Health Incorporated is incorporated in Indiana.
What is the principal executive office address of Elanco Animal Health Incorporated?
The principal executive office is located at 2500 Innovation Way, Greenfield, Indiana 46140.
What is the telephone number for Elanco Animal Health Incorporated?
The telephone number is (877) 352-6261.
Filing Stats: 606 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-07-09 08:30:21
Key Financial Figures
- $1.3 billion — nco or its affiliates for approximately $1.3 billion in cash payable at closing (the "Transa
- $1.3 billion — n. The purchase price was approximately $1.3 billion in cash, subject to customary post-clos
Filing Documents
- tm2419092d1_8k.htm (8-K) — 30KB
- tm2419092d1_ex99-1.htm (EX-99.1) — 9KB
- tm2419092d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-24-078464.txt ( ) — 217KB
- elan-20240709.xsd (EX-101.SCH) — 3KB
- elan-20240709_lab.xml (EX-101.LAB) — 33KB
- elan-20240709_pre.xml (EX-101.PRE) — 22KB
- tm2419092d1_8k_htm.xml (XML) — 3KB
01. Completion of Acquisition or
Item 2.01. Completion of Acquisition or Disposition of Assets. As previously disclosed, on February 5, 2024, Elanco Animal Health Incorporated, an Indiana corporation ("Elanco") entered into an Asset Purchase Agreement (as amended, modified or supplemented from time to time, the "Purchase Agreement") with Intervet International B.V., a Dutch private company with limited liability ("Buyer"), pursuant to which Buyer agreed to, from Elanco or its affiliates for approximately $1.3 billion in cash payable at closing (the "Transaction"). On July 9, 2024, Elanco, Buyer and their applicable affiliates consummated the Transaction. The purchase price was approximately $1.3 billion in cash, subject to customary post-closing adjustments set forth in the Purchase Agreement.
01. Regulation
Item 7.01. Regulation FD Disclosure. On July 9, 2024, Elanco issued a press announcing the completion of the Transaction, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in the accompanying Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
01. Financial
Item 9.01. Financial (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Elanco Animal Health Incorporated, dated as of July 9, 2024. 104.1 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elanco Animal Health Incorporated Date: July 9, 2024 By: /s/ Todd Young Name: Todd Young Title: Executive Vice President and Chief Financial Officer